As co-founder and CEO of LBT Innovations (ASX: LBT), she guided the company from early concept through ASX listing, global regulatory pathways, international partnerships and commercial launch, including establishing its European joint venture, Clever Culture Systems (ASX:CC5). In 2016 LBT was the first company, globally, to receive FDA clearance for its breakthrough AI technology for the recognition and reporting of microbial culture growth. Her work has shaped pathways for Australian medtech companies seeking to translate research into scalable, commercial products.

Over the past decade, Lusia has transitioned into governance and strategic advisory roles, bringing her commercial and technical expertise to organisations such as BioMelbourne Network (Chair) ANDHealth (NED), Neo-Bionica (Chair), 4Dx Limited (NED), ARMI, and the Australian Institute for Machine Learning.  Widely respected for her ability to bridge science, product development and international market strategy, she supports emerging ventures and research teams to navigate the path from idea to impact.

Lusia brings a wealth of experience in translation, medtech commercialisation and strategic governance—helping ensure research efforts are industry-aligned, implementable and globally competitive.

In June 2025, Lusia received a King’s Honour as Member of the Order of Australia (AM) in recognition of her work in the pharmaceutical, bioscience and medical technology industries.